

FIG. 1




FIG. 2
(SEQ ID NO: 1: murine Fc-IgG2a with IL2 signal sequence at the N-terminus)




FIG. 3
(SEQ ID NO: 3: human Fc-IgG1 with IL2 signal sequence at the N-terminus)




FIG. 4
(SEQ ID NO: 5: murine Fc-IgG2a with IL2 signal sequence at the N-terminus and hexa-histidine peptide at the C-terminus)




FIG. 5
(SEQ ID NO: 7: human Fc-IgG1 with IL2 signal sequence at the N-terminus and hexa-histidine peptide at the C-terminus)




FIG. 6
(SEQ ID NO: 9: human Fc-IgG1 with IL2 signal sequence at the N-terminus,
two additional cysteines in the hinge region, and hexa-histidine peptide at the C-terminus)




FIG. 7
(SEQ ID NO: 12: murine Fc-IgG2a with IL2 signal sequence at the N-terminus,
Asn to Ala substitution, and hexa-histidine peptide at the C-terminus)




FIG. 8
(SEQ ID NO: 14: human Fc-IgG1 with IL2 signal sequence at the N-terminus,
Asn to Ala substitution, and hexa-histidine peptide at the C-terminus)




FIG. 9
Conjugate 1





FIG. 10
Conjugate 2






FIG. 12
Conjugate 4




FIG. 13
Conjugate 5




FIG. 14
Conjugate 6




FIG. 15

H1N1 Neuraminidase IC₅₀ (uM)




FIG. 16
H1N1 Neuraminidase IC₅₀ (nM)




FIG. 17
H3N2 Neuraminidase IC₅₀ (nM)




FIG. 18B

Conjugate 4




FIG. 18C

Conjugate 6




FIG. 18A

Conjugate 3




FIG. 19A




FIG. 19B




FIG. 19C




FIG. 19D




FIG. 19E




FIG. 20A




FIG. 20B




FIG. 20C

A/California/04/09 H1N1 pdm




FIG. 20D

A/Vietnam/1203/04 H5N1 HALo






FIG. 20E

B/Lee/40 Victoria








FIG. 21D




FIG. 21E




FIG. 22A




FIG. 22B




FIG. 22C




FIG. 22D

B (B/Lee/40 Victoria)




FIG. 22E

H5N1 (A/Vietnam/1203/04)




FIG. 23

Conjugate 6 vs hlgG1
8 day mouse PK
50 mpk IV




FIG. 24
Mouse Weight




FIG. 25
Mouse Survival




FIG. 26
Mouse Weight




FIG. 27
Mouse Survival




FIG. 28




FIG. 29




FIG. 30




FIG. 31A




FIG. 31B




FIG. 31C




FIG. 31D




FIG. 31E




FIG. 31F




FIG. 32A




FIG. 32B




FIG. 32C




FIG. 32D




FIG. 32E




FIG. 32F




FIG. 33




FIG. 34A




FIG. 34B




FIG. 34C




FIG. 34D




FIG. 35
Mouse Weight




FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40
Conjugate 6 plasma and lung levels





FIG. 41
Conjugate 6 IV, SC, and IM administration







FIG. 43
Conjugate 6

FIG. 44
Conjugate 6 in vitro mouse plasma




FIG. 45
Conjugate 6 in vitro human plasma




FIG. 46
Conjugate 6 mouse liver microsomal stability




FIG. 47
Conjugate 6 human liver microsomal stability




FIG. 48
Conjugate 6 and Conjugate 12 *in vivo* efficacy




FIG. 49
Conjugate 6 and Conjugate 12 *in vivo* efficacy




FIG. 50
Conjugate 6 and Conjugate 12 *in vitro* Fcγ receptor IIIA binding




FIG. 51
Conjugate 6 and Conjugate 12 *in vitro* Fcγ receptor IIIA binding




FIG. 52
Toxicokinetics on days 1 and 8




FIG. 53
Mean plasma concentrations following 5 mg/kg IV or SC administration





FIG. 54
Conjugate 12






FIG. 56
Conjugate 6 *in vivo* efficacy in immune compromised mice




FIG. 57
Conjugate 6 *in vivo* efficacy in immune compromised mice




FIG. 58
Conjugate 6 dose-dependent viral clearance in lungs




FIG. 59
Conjugate 6 dose-dependent reduction in inflammatory cytokines in lungs




FIG. 60
Pharmacokinetics of Conjugate 6 in BALB/c SCID mice and CD-1 mice
5 mg/kg IV, single dose




FIG. 61
Conjugate 33

SEQ ID NO: 64




FIG. 62A

Influenza A/Puerto Rico/8/1934 (H1N1)




FIG. 62B

Influenza A/Puerto Rico/8/1934 (H1N1)




FIG. 63A




FIG. 63B




FIG. 64A




FIG. 64B




FIG. 65A

TNF α (Lung)




FIG. 65B

IL-6 (Lung)




FIG. 65C

INF γ (Lung)




FIG. 65D

MCP-1 (Lung)




FIG. 65E

MIP-1 α (Lung)




FIG. 66




FIG. 67




FIG. 68

